董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michel Detheux | 男 | Director | 60 | 11.94万美元 | 0.08 | 2025-12-31 |
| Andrew Levin | 男 | Independent Director | 48 | 3.19万美元 | 0.04 | 2025-12-31 |
| Wouter Joustra | 男 | Independent Director | 37 | 3.19万美元 | 0.04 | 2025-12-31 |
| Jean Paul Kress | -- | Chief Executive Officer, President and Chairman of the Board | -- | 6502.76万美元 | 未持股 | 2025-12-31 |
| Erez Kalir | -- | Independent Director | -- | 12.30万美元 | 0.29 | 2025-12-31 |
| Fouad Namouni | -- | Independent Director | -- | 5.11万美元 | 0.51 | 2025-12-31 |
| Alexander Cumbo | 男 | Director | 55 | 12.14万美元 | 0.08 | 2025-12-31 |
| Daniella Beckman | 女 | Independent Director | 47 | 6.42万美元 | 0.82 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jean Paul Kress | -- | Chief Executive Officer, President and Chairman of the Board | -- | 6502.76万美元 | 未持股 | 2025-12-31 |
| Amy Quinlan | -- | Vice President, Finance | -- | 未披露 | 未持股 | 2025-12-31 |
| Sandesh Mahatme | 男 | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | 60 | 3940.61万美元 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Michel Detheux
-
自成立以来，Michel Detheux一直担任我们的首席执行官和董事。Detheux博士之前从2010年12月到2012年3月担任Ludwig Cancer Research的董事。在此之前，Detheux博士在Ogeda F/K/A Eurocreen担任多个科学职位。Detheux博士拥有Université；Catholique de Louvain的生物化学学位和博士学位以及Solvay Business School的商业证书。
Michel Detheux,is President and Chief Executive Officer of iTeos Therapeutics, which he co-founded and led from discovery to late-stage clinical development. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company's lead anti-TIGIT antibody. Prior to founding iTeos, Dr. Detheux was a Director at Ludwig Cancer Research and held scientific and business development roles at Euroscreen (now Ogeda). He currently serves as Chairman of the Board at Egle Therapeutics. Dr. Detheux holds a Ph.D. in Biochemistry and a degree in Bioengineering from Université Catholique de Louvain. - 自成立以来，Michel Detheux一直担任我们的首席执行官和董事。Detheux博士之前从2010年12月到2012年3月担任Ludwig Cancer Research的董事。在此之前，Detheux博士在Ogeda F/K/A Eurocreen担任多个科学职位。Detheux博士拥有Université；Catholique de Louvain的生物化学学位和博士学位以及Solvay Business School的商业证书。
- Michel Detheux,is President and Chief Executive Officer of iTeos Therapeutics, which he co-founded and led from discovery to late-stage clinical development. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company's lead anti-TIGIT antibody. Prior to founding iTeos, Dr. Detheux was a Director at Ludwig Cancer Research and held scientific and business development roles at Euroscreen (now Ogeda). He currently serves as Chairman of the Board at Egle Therapeutics. Dr. Detheux holds a Ph.D. in Biochemistry and a degree in Bioengineering from Université Catholique de Louvain.
- Andrew Levin
-
Andrew Levin是Eliem的联合创始人，从2018年10月到2020年10月担任我们的首席执行官，自2019年2月以来担任我们的董事会主席。自2015年以来，Levin博士一直担任RA Capital Management，L.P.的投资团队的常务董事。此前，Levin博士曾担任H.I.G.BioVentures的副总裁，在此之前，他曾担任Clinton Health Access Initiative的药物科学总监。Levin博士拥有普林斯顿大学机械工程学士学位，麻省理工学院生物医学工程博士学位和哈佛医学院硕士学位。
Andrew Levin has served as a member of board of directors since September 2024. Previoly, Dr. Levin served as the President and Founder of Carnot Pharma from 2016 to 2022. Dr. Levin is also a Co Founder of Eliem Therapeutics, Inc. (now Climb Bio, Inc. (Nasdaq: CLYM)) where he served as Chief Executive Officer from October 2018 to October 2020, and has served on the board of directors since February 2019 and as Executive Chairman of the board of directors since February 2023. Since 2015, Dr. Levin has served as a Managing Director on the Investment Team at RA Capital Management, L.P. Previoly, Dr. Levin was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a BS in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachetts Institute of Technology and an MD from Harvard Medical School. - Andrew Levin是Eliem的联合创始人，从2018年10月到2020年10月担任我们的首席执行官，自2019年2月以来担任我们的董事会主席。自2015年以来，Levin博士一直担任RA Capital Management，L.P.的投资团队的常务董事。此前，Levin博士曾担任H.I.G.BioVentures的副总裁，在此之前，他曾担任Clinton Health Access Initiative的药物科学总监。Levin博士拥有普林斯顿大学机械工程学士学位，麻省理工学院生物医学工程博士学位和哈佛医学院硕士学位。
- Andrew Levin has served as a member of board of directors since September 2024. Previoly, Dr. Levin served as the President and Founder of Carnot Pharma from 2016 to 2022. Dr. Levin is also a Co Founder of Eliem Therapeutics, Inc. (now Climb Bio, Inc. (Nasdaq: CLYM)) where he served as Chief Executive Officer from October 2018 to October 2020, and has served on the board of directors since February 2019 and as Executive Chairman of the board of directors since February 2023. Since 2015, Dr. Levin has served as a Managing Director on the Investment Team at RA Capital Management, L.P. Previoly, Dr. Levin was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a BS in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachetts Institute of Technology and an MD from Harvard Medical School.
- Wouter Joustra
-
董事会非独立成员Wouter Joustra于2019年加入Forbion，担任合伙人，目前担任Forbion Growth Fund的普通合伙人。在Forbion，Wouter负责交易发起、投资组合管理和撤资策略。此前，Wouter是Kempen&Co的高级交易员生命科学和医疗保健，这是一家欧洲投资银行，拥有专门的生命科学和医疗保健专营权。在这个职位上，他负责积极运营Kempen&Co的交易组合，在那里他参与交易结构，股权资本市场交易，以及公司股票的大宗交易。在Kempen&Co，Wouter也是生命科学专营权的执行董事会成员，负责定义和执行利基的战略和预算。Wouter拥有硕士学位。荷兰格罗宁根大学工商管理专业。
Wouter Joustra has served as a member of the Board since May 15, 2024. He is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for deal origination, general portfolio management and divestment strategies, and foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Jotra managed Kempen's trading portfolio, and was involved in deal structuring and equity capital markets transactions, as ll as larger block trades. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corp. until the completion of the biness combination of enGene Holdings Inc. in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, Beacon Therapeutics, Navigator Medicines, Verdiva Bio and NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Jotra holds an M.Sc. in Biness Administration and a B.Sc. in International Biness and Management from the University of Groningen. - 董事会非独立成员Wouter Joustra于2019年加入Forbion，担任合伙人，目前担任Forbion Growth Fund的普通合伙人。在Forbion，Wouter负责交易发起、投资组合管理和撤资策略。此前，Wouter是Kempen&Co的高级交易员生命科学和医疗保健，这是一家欧洲投资银行，拥有专门的生命科学和医疗保健专营权。在这个职位上，他负责积极运营Kempen&Co的交易组合，在那里他参与交易结构，股权资本市场交易，以及公司股票的大宗交易。在Kempen&Co，Wouter也是生命科学专营权的执行董事会成员，负责定义和执行利基的战略和预算。Wouter拥有硕士学位。荷兰格罗宁根大学工商管理专业。
- Wouter Joustra has served as a member of the Board since May 15, 2024. He is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for deal origination, general portfolio management and divestment strategies, and foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Jotra managed Kempen's trading portfolio, and was involved in deal structuring and equity capital markets transactions, as ll as larger block trades. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corp. until the completion of the biness combination of enGene Holdings Inc. in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, Beacon Therapeutics, Navigator Medicines, Verdiva Bio and NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Jotra holds an M.Sc. in Biness Administration and a B.Sc. in International Biness and Management from the University of Groningen.
- Jean Paul Kress
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Erez Kalir
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Fouad Namouni
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alexander Cumbo
-
Alexander Cumbo，自2025年3月起担任董事会成员。Cumbo先生自2022年12月起担任生命科学公司Solid Biosciences Inc.的总裁兼首席执行官和董事。在此之前，Cumbo先生曾在2020年10月至2022年12月期间担任总裁兼首席执行官，并担任基因治疗公司AavantiBio，Inc.或AavantiBio的董事，当时Solid Bio收购了AavantiBio。从2013年1月至2020年10月，Cumbo先生在精准基因医学公司Sarepta Therapeutics, Inc.担任越来越重要的职务，最终担任执行副总裁和首席商务官。从2011年到2013年，Cumbo先生担任Vertex Pharmaceuticals Incorporated或福泰制药一家生物技术公司的销售和治疗教育副总裁，推出丙型肝炎的治疗药物Incivek。从2010年到2011年，他担任福泰制药的区域总监。在加入福泰制药之前，Cumbo先生曾在生物制药公司吉利德科学公司担任多个商业职务，为HIV、HBV和心血管领域的特许经营权提供支持。Cumbo先生自2022年6月起担任Verve Therapeutics董事会成员。Cumbo先生此前曾于2018年11月至2020年4月在Ra Pharmaceuticals, Inc.的董事会任职，该公司是一家临床阶段的生物制药公司，被布鲁塞尔UCB收购。Cumbo先生获得了奥本大学实验室技术理学学士学位。
Alexander Cumbo,has been a member of board of directors since March 2025. Mr. Cumbo has served as the President and Chief Executive Officer and as a director of Solid Biosciences Inc., a life sciences company, or Solid Bio, since December 2022. Prior to that, Mr. Cumbo served as the President and Chief Executive Officer and as a director of AavantiBio, Inc., or AavantiBio, a gene therapy company, from October 2020 to December 2022, when Solid Bio acquired AavantiBio. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, or Vertex, a biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo has served on the board of directors of Verve Therapeutics, Inc. since June 2022. Mr. Cumbo previously served on the Board of Directors of Ra Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University. - Alexander Cumbo，自2025年3月起担任董事会成员。Cumbo先生自2022年12月起担任生命科学公司Solid Biosciences Inc.的总裁兼首席执行官和董事。在此之前，Cumbo先生曾在2020年10月至2022年12月期间担任总裁兼首席执行官，并担任基因治疗公司AavantiBio，Inc.或AavantiBio的董事，当时Solid Bio收购了AavantiBio。从2013年1月至2020年10月，Cumbo先生在精准基因医学公司Sarepta Therapeutics, Inc.担任越来越重要的职务，最终担任执行副总裁和首席商务官。从2011年到2013年，Cumbo先生担任Vertex Pharmaceuticals Incorporated或福泰制药一家生物技术公司的销售和治疗教育副总裁，推出丙型肝炎的治疗药物Incivek。从2010年到2011年，他担任福泰制药的区域总监。在加入福泰制药之前，Cumbo先生曾在生物制药公司吉利德科学公司担任多个商业职务，为HIV、HBV和心血管领域的特许经营权提供支持。Cumbo先生自2022年6月起担任Verve Therapeutics董事会成员。Cumbo先生此前曾于2018年11月至2020年4月在Ra Pharmaceuticals, Inc.的董事会任职，该公司是一家临床阶段的生物制药公司，被布鲁塞尔UCB收购。Cumbo先生获得了奥本大学实验室技术理学学士学位。
- Alexander Cumbo,has been a member of board of directors since March 2025. Mr. Cumbo has served as the President and Chief Executive Officer and as a director of Solid Biosciences Inc., a life sciences company, or Solid Bio, since December 2022. Prior to that, Mr. Cumbo served as the President and Chief Executive Officer and as a director of AavantiBio, Inc., or AavantiBio, a gene therapy company, from October 2020 to December 2022, when Solid Bio acquired AavantiBio. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, or Vertex, a biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo has served on the board of directors of Verve Therapeutics, Inc. since June 2022. Mr. Cumbo previously served on the Board of Directors of Ra Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University.
- Daniella Beckman
-
Daniella Beckman，自2012年6月起担任5：01 Acquisition的高级副总裁、首席财务官和财务主管。Bechman女士自2019年9月起担任Tango Therapeutics，Inc.的首席财务官。在加入Tango之前，Beckman女士于2015年11月至2019年9月期间通过Beckman Consulting LLC为早期生物技术公司提供咨询和临时首席财务官服务。Beckman女士是Idenix Pharmaceuticals的首席财务官，直到Idenix Pharmaceuticals于2014年被默沙东收购。Beckman女士担任Translate Bio, Inc.纳斯达克：TBIO和Vor Biopharma，Inc.（纳斯达克：VOR）董事会审计委员会主席。Beckman女士拥有波士顿大学工商管理/会计学学士学位，是马萨诸塞州的注册会计师。
Daniella Beckman has served on 5:01 Acquisition board of directors since the completion of 5:01 Acquisition IPO. Ms. Bechman has served as the chief financial officer of Tango Therapeutics, Inc. since September 2019. Prior to Tango, Ms. Beckman provided consulting and interim chief financial officer services for early- stage biotechnology companies through Beckman Consulting LLC from November 2015 to September 2019. Prior to consulting, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until its acquisition by Merck in 2014. Ms. Beckman serves as Chair of Audit Committee for the boards of directors of Translate Bio, Inc. Nasdaq: TBIO and Vor Biopharma, Inc. (Nasdaq: VOR). Ms. Beckman has a B.S. in business administration/accounting from Boston University and is a certified public accountant in Massachusetts. - Daniella Beckman，自2012年6月起担任5：01 Acquisition的高级副总裁、首席财务官和财务主管。Bechman女士自2019年9月起担任Tango Therapeutics，Inc.的首席财务官。在加入Tango之前，Beckman女士于2015年11月至2019年9月期间通过Beckman Consulting LLC为早期生物技术公司提供咨询和临时首席财务官服务。Beckman女士是Idenix Pharmaceuticals的首席财务官，直到Idenix Pharmaceuticals于2014年被默沙东收购。Beckman女士担任Translate Bio, Inc.纳斯达克：TBIO和Vor Biopharma，Inc.（纳斯达克：VOR）董事会审计委员会主席。Beckman女士拥有波士顿大学工商管理/会计学学士学位，是马萨诸塞州的注册会计师。
- Daniella Beckman has served on 5:01 Acquisition board of directors since the completion of 5:01 Acquisition IPO. Ms. Bechman has served as the chief financial officer of Tango Therapeutics, Inc. since September 2019. Prior to Tango, Ms. Beckman provided consulting and interim chief financial officer services for early- stage biotechnology companies through Beckman Consulting LLC from November 2015 to September 2019. Prior to consulting, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until its acquisition by Merck in 2014. Ms. Beckman serves as Chair of Audit Committee for the boards of directors of Translate Bio, Inc. Nasdaq: TBIO and Vor Biopharma, Inc. (Nasdaq: VOR). Ms. Beckman has a B.S. in business administration/accounting from Boston University and is a certified public accountant in Massachusetts.
高管简历
中英对照 | 中文 | 英文- Jean Paul Kress
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Amy Quinlan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sandesh Mahatme
Sandesh Mahatme，自2015年6月起担任董事。自2012年11月以来，Mahatme先生曾担任多个行政职务，包括在上市的生物制药公司Sarepta Therapeutics, Inc.担任执行副总裁、首席财务官和首席商务官。2006年1月至2012年11月，Mahatme先生曾任职于上市生物制药公司新基医药公司，担任过多个职务，包括企业发展高级副总裁、财务高级副总裁、公司财务主管和税务主管。从1997年到2005年，Mahatme先生曾任职于制药公司辉瑞公司，在业务发展和公司税务方面担任高级职务。Mahatme先生目前在Flexion Therapeutics，Inc.和Elcelyx Therapeutics，Inc.的董事会任职，这两家公司均为生物制药公司。Mahatme先生在康奈尔大学法学院和纽约大学法学院获得法学硕士学位，并且是纽约州律师协会的成员。
Sandesh Mahatme has served as a director since June 2015. Since November 2012 Mr. Mahatme has served in various executive positions, including as Executive Vice President, Chief Financial Officer, and Chief Business Officer at Sarepta Therapeutics, Inc., a publicly traded biopharmaceutical company. From January 2006 to November 2012 Mr. Mahatme worked at Celgene Corporation, a publicly traded biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. From 1997 to 2005 Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, where he served in senior roles in business development and corporate tax. Mr. Mahatme currently serves on the boards of directors of Flexion Therapeutics, Inc. and Elcelyx Therapeutics, Inc., both biopharmaceutical companies. Mr. Mahatme earned LL.M. degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association.- Sandesh Mahatme，自2015年6月起担任董事。自2012年11月以来，Mahatme先生曾担任多个行政职务，包括在上市的生物制药公司Sarepta Therapeutics, Inc.担任执行副总裁、首席财务官和首席商务官。2006年1月至2012年11月，Mahatme先生曾任职于上市生物制药公司新基医药公司，担任过多个职务，包括企业发展高级副总裁、财务高级副总裁、公司财务主管和税务主管。从1997年到2005年，Mahatme先生曾任职于制药公司辉瑞公司，在业务发展和公司税务方面担任高级职务。Mahatme先生目前在Flexion Therapeutics，Inc.和Elcelyx Therapeutics，Inc.的董事会任职，这两家公司均为生物制药公司。Mahatme先生在康奈尔大学法学院和纽约大学法学院获得法学硕士学位，并且是纽约州律师协会的成员。
- Sandesh Mahatme has served as a director since June 2015. Since November 2012 Mr. Mahatme has served in various executive positions, including as Executive Vice President, Chief Financial Officer, and Chief Business Officer at Sarepta Therapeutics, Inc., a publicly traded biopharmaceutical company. From January 2006 to November 2012 Mr. Mahatme worked at Celgene Corporation, a publicly traded biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. From 1997 to 2005 Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, where he served in senior roles in business development and corporate tax. Mr. Mahatme currently serves on the boards of directors of Flexion Therapeutics, Inc. and Elcelyx Therapeutics, Inc., both biopharmaceutical companies. Mr. Mahatme earned LL.M. degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association.